TY - JOUR
T1 - Lowering Low-Density Lipoprotein Cholesterol
T2 - Statins, Ezetimibe, Bile Acid Sequestrants, and Combinations: Comparative Efficacy and Safety
AU - Hou, Runhua
AU - Goldberg, Anne Carol
N1 - Funding Information:
ACG has received grant and/or research support from Abbott, Aegerion, Astra Zeneca, Glaxo-Smith-Kline, ISIS, Merck, Pfizer, Sanofi-Aventis, Sankyo, and Takeda. ACG has served as a consultant to Abbott, Unilever, Roche, and Sanofi-Aventis. ACG has served on the Merck-Schering-Plough Speaker's Bureau. ACG has received travel support from Sanofi-Aventis and speaking honoraria from Abbott.
PY - 2009/3
Y1 - 2009/3
N2 - Statins, ezetimibe, and bile acid-binding resins can be used individually or in combination for lowering low-density lipoprotein cholesterol (LDL-C) levels. Statins are the most potent drugs for lowering LDL-C and are well tolerated in most patients. The addition of a bile acid sequestrant or ezetimibe to a statin produces additional LDL-C reduction allowing many patients to reach LDL-C targets. This article discusses the efficacy and safety of available statins, bile acid sequestrants, and ezetimibe in the treatment of hyperlipidemia.
AB - Statins, ezetimibe, and bile acid-binding resins can be used individually or in combination for lowering low-density lipoprotein cholesterol (LDL-C) levels. Statins are the most potent drugs for lowering LDL-C and are well tolerated in most patients. The addition of a bile acid sequestrant or ezetimibe to a statin produces additional LDL-C reduction allowing many patients to reach LDL-C targets. This article discusses the efficacy and safety of available statins, bile acid sequestrants, and ezetimibe in the treatment of hyperlipidemia.
KW - Bile acid sequestrants
KW - Efficacy
KW - Ezetimibe
KW - LDL-C
KW - Safety
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=59949088249&partnerID=8YFLogxK
U2 - 10.1016/j.ecl.2008.11.007
DO - 10.1016/j.ecl.2008.11.007
M3 - Review article
C2 - 19217513
AN - SCOPUS:59949088249
VL - 38
SP - 79
EP - 97
JO - Endocrinology and Metabolism Clinics of North America
JF - Endocrinology and Metabolism Clinics of North America
SN - 0889-8529
IS - 1
ER -